{"id":477044,"date":"2021-04-15T09:18:10","date_gmt":"2021-04-15T13:18:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/"},"modified":"2021-04-15T09:18:10","modified_gmt":"2021-04-15T13:18:10","slug":"adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/","title":{"rendered":"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting"},"content":{"rendered":"

<\/p>\n

Adamas Announces Two Presentations for the American Academy of Neurology 73rd<\/sup> Annual Meeting<\/b><\/p>\n

EMERYVILLE, Calif.–(BUSINESS WIRE<\/a>)–
\nAdamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Meeting. One of the presentations will focus on GOCOVRI\u00ae (amantadine) extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson\u2019s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa\/carbidopa in patients with Parkinson\u2019s disease experiencing OFF episodes. The second presentation will feature a survey exploring the impact of dyskinesia and OFF time in people living with PD.\n<\/p>\n

\n\u201cData presented at this year\u2019s AAN Annual Meeting highlight the widespread prevalence of motor complications and associated negative social and emotional impacts on people with Parkinson\u2019s and their care partners and also supports GOCOVRI\u2019s unique clinical profile to treat both OFF and dyskinesia motor complications in Parkinson\u2019s disease,\u201d said Adrian Quartel, M.D., Chief Medical Officer. \u201cWe will present new data analyses of our pivotal trials evaluating the treatment impact of GOCOVRI in increasing ON time without any dyskinesia. As the only medication approved to treat OFF and dyskinesia, GOCOVRI may be an appropriate treatment option for people with PD experiencing either end of the spectrum of levodopa-related motor complications (OFF or dyskinesia) or both.\u201d\n<\/p>\n

\nThe posters will be available for on-demand viewing the duration of the virtual meeting, April 17 \u2013 22, 2021 from 7:00 am \u2013 5:00 pm EDT. Poster details as follows:<\/b><\/p>\n

GOCOVRI poster presentation<\/span><\/b><\/p>\n

Title: <\/b>ADS-5102 significantly increases ON time without dyskinesia: Pooled patient diary analyses from Parkinson\u2019s disease pivotal trials
\n
Session name: <\/b>P14: Clinical Trials, Surveys, and Studies in Movement Disorders
\n
Lead author:<\/b> Robert A. Hauser, M.D., University of South Florida
\n
Program number:<\/b> P14.128\n<\/p>\n

Disease state poster presentation<\/span><\/b><\/p>\n

Title: <\/b>Evaluating the impact of levodopa-induced dyskinesia and OFF time in persons affected by Parkinson\u2019s disease: Results of a PMD Alliance survey
\n
Session name: <\/b>P14: Clinical Trials, Surveys, and Studies in Movement Disorders
\n
Lead author<\/b>: Jill Farmer, D.O., M.P.H., Drexel University and the Global Neurosciences Institute
\n
Program number: <\/b>P14.148\n<\/p>\n

About Parkinson\u2019s disease, OFF and dyskinesia<\/b><\/p>\n

\nParkinson\u2019s disease (PD) is a progressive, neurodegenerative disorder caused by the gradual loss of brain cells that produce the neurotransmitter dopamine and affects approximately one million people in the United States. Dopamine decline in the brain results in a wide range of motor (movement-related) and non-motor symptoms. As the disease progresses, people taking levodopa-based therapy are likely to experience reemergence or sudden return of stiffness, rigidity and tremors between medication doses, referred to as OFF episodes, which may be unpredictable. The primary treatment for PD is with levodopa; however, over time levodopa may lead to involuntary, uncontrolled movements known as dyskinesia. The abrupt and unpredictable transitions between episodes of dyskinesia, normal movement, and OFF lead to considerable impact on patients\u2019 lives.\n<\/p>\n

About GOCOVRI<\/b><\/p>\n

\nGOCOVRI\u00ae (amantadine) extended-release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson\u2019s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa\/carbidopa in patients with Parkinson\u2019s disease experiencing OFF episodes.\n<\/p>\n

\nTaken once daily at bedtime, GOCOVRI provides an initial lag (delayed release) and a slow rise in amantadine concentration during the night, resulting in a high concentration from the morning and throughout the waking day (extended release). Additionally, in the clinical trials, the adjunctive use of GOCOVRI did not require dose changes to dopaminergic therapies. The most commonly observed adverse reactions with GOCOVRI were hallucinations, dizziness, dry mouth, peripheral edema, constipation, falls and orthostatic hypotension.\n<\/p>\n

\nFor more information about GOCOVRI, please visit www.GOCOVRI.com<\/a>.\n<\/p>\n

IMPORTANT SAFETY INFORMATION
\n
<\/b>CONTRAINDICATIONS
\n
GOCOVRI is contraindicated in patients with creatinine clearance below 15 mL\/min\/1.73 m2\n<\/p>\n

\nWARNINGS AND PRECAUTIONS
\n
Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson\u2019s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.\n<\/p>\n

\nSuicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.\n<\/p>\n

\nHallucinations\/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.\n<\/p>\n

\nDizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.\n<\/p>\n

\nWithdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson\u2019s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI.\n<\/p>\n

\nImpulse Control\/Compulsive Behaviors: Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications.\n<\/p>\n

\nADVERSE REACTIONS
\n
The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and, orthostatic hypotension.\n<\/p>\n

\nPlease see full Prescribing Information for additional important safety information at https:\/\/www.gocovri.com\/assets\/pdfs\/Gocovri_Prescribing_Information.pdf<\/a>.\n<\/p>\n

About Adamas<\/b><\/p>\n

\nAt Adamas our vision is clear \u2013 to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com<\/a>.\n<\/p>\n

\nSource: Adamas Pharmaceuticals, Inc.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210415005240\/en\/<\/a><\/span><\/p>\n

Media:
\n<\/b>
Sarah Mathieson
\n
Vice President of Corporate Communications
\n
510-450-3528
\n
smathieson@adamaspharma.com<\/a><\/p>\n

Investors:
\n<\/b>
Peter Vozzo
\n
Managing Director, Westwicke
\n
443-213-0505
\n
peter.vozzo@westwicke.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting EMERYVILLE, Calif.–(BUSINESS WIRE)– Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Meeting. One of the presentations will focus on GOCOVRI\u00ae (amantadine) extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson\u2019s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa\/carbidopa in patients with Parkinson\u2019s disease experiencing OFF episodes. The second presentation will feature a survey exploring the impact of … <\/p>\n

Continue reading “Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-477044","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAdamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting EMERYVILLE, Calif.–(BUSINESS WIRE)– Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Meeting. One of the presentations will focus on GOCOVRI\u00ae (amantadine) extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson\u2019s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa\/carbidopa in patients with Parkinson\u2019s disease experiencing OFF episodes. The second presentation will feature a survey exploring the impact of … Continue reading "Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-15T13:18:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210415005240r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting\",\"datePublished\":\"2021-04-15T13:18:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/\"},\"wordCount\":1066,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210415005240r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/\",\"name\":\"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210415005240r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-04-15T13:18:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210415005240r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210415005240r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting - Market Newsdesk","og_description":"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting EMERYVILLE, Calif.–(BUSINESS WIRE)– Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Meeting. One of the presentations will focus on GOCOVRI\u00ae (amantadine) extended-release capsules, the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson\u2019s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and as an adjunctive treatment to levodopa\/carbidopa in patients with Parkinson\u2019s disease experiencing OFF episodes. The second presentation will feature a survey exploring the impact of … Continue reading \"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-15T13:18:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210415005240r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting","datePublished":"2021-04-15T13:18:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/"},"wordCount":1066,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210415005240r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/","name":"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210415005240r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-04-15T13:18:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210415005240r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210415005240r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamas-announces-two-presentations-for-the-american-academy-of-neurology-73rd-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/477044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=477044"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/477044\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=477044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=477044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=477044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}